## Alberto Briganti

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/10749942/alberto-briganti-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26,721 131 929 79 h-index g-index citations papers 6.84 33,396 1,025 5.4 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
929	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer <i>Prostate International</i> , <b>2022</b> , 10, 21-27	3.4	
928	Clinical Case Debate: Immunotherapy Versus Alternative Therapies in the Neoadjuvant and Adjuvant Setting of Localized, High-Risk Prostate Cancer <b>2022</b> , 145-160		
927	Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press.	10.2	
926	Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2022</b> ,	2.8	2
925	Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102360	14.4	1
924	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer <i>World Journal of Urology</i> , <b>2022</b> , 1	4	О
923	Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol 2022;81:5-33 <i>European Urology</i> , <b>2022</b> ,	10.2	
922	Re: Dries Develtere, Giuseppe Rosiello, Pietro Piazza, et al. Early Catheter Removal on Postoperative Day 2 After Robot-assisted Radical Prostatectomy: Updated Real-life Experience with the Aalst Technique. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.10.003	5.1	
921	European Urology Focus, 2022, Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes European Urology Open Science, 2022, 38, 10-11	0.9	1
920	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. <i>Minerva Urology and Nephrology</i> , <b>2022</b> , 74,	2.3	1
919	Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. <i>Prostate</i> , <b>2022</b> , 82, 120-131	4.2	1
918	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. <i>Prostate</i> , <b>2022</b> , 82, 78-85	4.2	1
917	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2022</b> , 40, 10.e1-10.e6	2.8	2
916	Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter. <i>Journal of Urology</i> , <b>2022</b> , 207, 242	2.5	
915	Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer <i>Prostate</i> , <b>2022</b> ,	4.2	1
914	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration <i>World Journal of Urology</i> , <b>2022</b> , 1	4	0
913	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables <i>Journal of Racial and Ethnic Health Disparities</i> , <b>2022</b> , 1	3.5	O

### (2021-2022)

912	Re: K.R. Seetharam Bhat, Marcio Covas Moschovas, Marco Sandri, et al. Outcomes of Salvage Robot-assisted Radical Prostatectomy After Focal Ablation for Prostate Cancer in Comparison to Primary Robot-assisted Radical Prostatectomy: A Matched Analysis. Eur Urol Focus. In press.	5.1	
911	https://doi.org/10.1016/j.euf.2021.10.005 European Urology Focus, 2022,  Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and  Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy Cancers, 2022, 14,	6.6	2
910	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 European Urology, 2022,	10.2	2
909	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium <i>European Urology</i> , <b>2022</b> ,	10.2	1
908	Radiomic and gEnomic approaches for the enhanced Diagnosis of clear cell REnal Cancer (REDIRECt): a translational pilot methodological study <i>Translational Andrology and Urology</i> , <b>2022</b> , 11, 149-158	2.3	1
907	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2022</b> , 20, 71-80	1.7	Ο
906	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality <i>Cancer Causes and Control</i> , <b>2022</b> , 33, 769	2.8	
905	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review <i>BMJ Open</i> , <b>2022</b> , 12, e058267	3	O
904	Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy <i>World Journal of Urology</i> , <b>2022</b> , 1	4	1
903	Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity <i>International Urology and Nephrology</i> , <b>2022</b> , 1	2.3	1
902	Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 751	3.6	
901	Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. Surgical Oncology, <b>2022</b> , 101783	2.5	Ο
900	Differences between rural and urban prostate cancer patients. World Journal of Urology, 2021, 39, 2507	- <b>2</b> 514	8
899	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , <b>2021</b> , 4, 580-593	6.7	7
898	Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. <i>European Urology Focus</i> , <b>2021</b> , 7, 818-826	5.1	2
897	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , <b>2021</b> , 4, 829-833	6.7	8
896	Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. <i>European Urology Oncology</i> , <b>2021</b> , 4, 594-600	6.7	5
895	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2021</b> .	4.4	2

894	Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , <b>2021</b> ,	2.3	2
893	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 778858	5.3	1
892	Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. <i>International Urology and Nephrology</i> , <b>2021</b> , 54, 81	2.3	1
891	Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 40, 37-37	2.8	
890	Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. <i>European Urology Oncology</i> , <b>2021</b> ,	6.7	2
889	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. <i>Minerva Urology and Nephrology</i> , <b>2021</b> , 73, 610-6	5 <del>7</del> 5 <sup>3</sup>	4
888	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , <b>2021</b> , 374, 216-224	33.3	28
887	Improving Guideline Adherence in Urology. European Urology Focus, 2021,	5.1	1
886	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 754996	5.3	
885	Reimagining prostate cancer screening: the IMPACT of germline mutations. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1491-1492	21.7	1
88 <sub>5</sub>		21.7 5.1	1 O
	<b>2021</b> , 22, 1491-1492	•	
884	Evidence-based Urology: Surrogate Endpoints - For. <i>European Urology Focus</i> , <b>2021</b> , 7, 1217-1218  How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. <i>Urologic Oncology:</i>	5.1	0
884	Evidence-based Urology: Surrogate Endpoints - For. <i>European Urology Focus</i> , <b>2021</b> , 7, 1217-1218  How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 40, 103.e17-103.e17  Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.	5.1	0
884 883 882	Evidence-based Urology: Surrogate Endpoints - For. <i>European Urology Focus</i> , <b>2021</b> , 7, 1217-1218  How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 40, 103.e17-103.e17  Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , <b>2021</b> , 4, 697-713  Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in	5.1 2.8 6.7	O O 2O
884 883 882	Evidence-based Urology: Surrogate Endpoints - For. European Urology Focus, 2021, 7, 1217-1218  How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 103.e17-103.e17  Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 697-713  Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. European Urology Focus, 2021, 7, 1067-1074  The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial	5.1 2.8 6.7 5.1	O O 2O 2
884 883 882 881	Evidence-based Urology: Surrogate Endpoints - For. European Urology Focus, 2021, 7, 1217-1218  How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 103.e17-103.e17  Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 697-713  Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. European Urology Focus, 2021, 7, 1067-1074  The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). Clinical Genitourinary Cancer, 2021, 19, 272.e1-272.e7  Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal	<ul><li>5.1</li><li>2.8</li><li>6.7</li><li>5.1</li><li>3.3</li></ul>	o 20 2 5

### (2021-2021)

876	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , <b>2021</b> , 7, 1092-1099	5.1	1
875	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. <i>World Journal of Urology</i> , <b>2021</b> , 39, 1947-1953	4	1
874	The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery. <i>World Journal of Urology</i> , <b>2021</b> , 39, 2553-2558	4	6
873	Re: Kathrin Meisterhofer, Sereina Herzog, Karin A. Strini, Luca Sebastianelli, Ricarda Bauer, Orietta Dalpiaz. Male Slings for Postprostatectomy Incontinence: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:575-92. <i>European Urology Focus</i> , <b>2021</b> , 7, 1205-1206	5.1	
872	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. <i>Prostate</i> , <b>2021</b> , 81, 339-346	4.2	8
871	Advanced Imaging Analysis in Prostate MRI: Building a Radiomic Signature to Predict Tumor Aggressiveness. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	5
870	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , <b>2021</b> , 32, 627-634	2.8	4
869	Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 4028-4041	8.8	6
868	Metastatic hormone-sensitive prostate cancer: local treatment strategies. <i>World Journal of Urology</i> , <b>2021</b> , 1	4	O
867	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	2
866	Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond. <i>European Urology Focus</i> , <b>2021</b> , 7, 245-2	4 <sup>5</sup> 9 <sup>1</sup>	2
865	Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	5
864	Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	1
863	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	7
862	Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , <b>2021</b> , 4, 134-149	6.7	9
861	Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 784.e1-784.e9	2.8	Ο
860	Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3921-3930	4	4
859	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 239.e1-239.e7	2.8	O

858	Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	1
857	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , <b>2021</b> ,	6.7	1
856	Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 1137-1142	6.2	О
855	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , <b>2021</b> , 7, 598-607	5.1	1
854	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly An International Multicenter Study. <i>Bladder Cancer</i> , <b>2021</b> , 7, 173-185	1	
853	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 785.e11-785.	.2187 .e17	4
852	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. <i>World Journal of Urology</i> , <b>2021</b> , 39, 4085-4099	4	2
851	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3781-3787	4	4
850	Re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537-44: Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion?. <i>European Urology</i> , <b>2021</b> , 79, e132-e133	10.2 3	
849	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 765-771	4.2	1
848	Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study. <i>International Journal of Urology</i> , <b>2021</b> , 28, 834-839	2.3	3
847	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.  International Journal of Urology, 2021, 28, 862-869	2.3	8
846	Re: Paolo Dell'Oglio, Elio Mazzone, Edward Lambert, et al. The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in	5.1	
845	Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. In press.	10.2	1
844	Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. <i>European Urology Focus</i> , <b>2021</b> , 7, 644-652	5.1	11
843	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 1707-1713	4.2	1
842	Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. <i>European Urology</i> , <b>2021</b> , 80, 730-737	10.2	1
841	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Letter. <i>Journal of Urology</i> , <b>2021</b> , 205, 1839	2.5	

840	Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review. <i>Journal of Urology</i> , <b>2021</b> , 205, 1569-1576	2.5	0
839	High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?. <i>Current Problems in Cancer</i> , <b>2021</b> , 45, 100759	2.3	O
838	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 789.e9-789.e17	2.8	1
837	Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 785.e19-785.e27	2.8	1
836	Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. <i>Prostate</i> , <b>2021</b> , 81, 874-881	4.2	5
835	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited.	6.7	
834	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 1729-1735	4.2	0
833	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis.  Minerva Urology and Nephrology, 2021,	2.3	1
832	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. <i>Current Oncology</i> , <b>2021</b> , 28, 2881-2892	2.8	O
831	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 788.e7-788.e13	2.8	2
830	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. <i>World Journal of Urology</i> , <b>2021</b> , 39, 461-472	4	8
829	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. <i>World Journal of Urology</i> , <b>2021</b> , 39, 443-451	4	4
828	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 48-53	9.7	15
827	Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. <i>European Urology</i> , <b>2021</b> , 79, 44-53	10.2	29
826	How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. <i>World Journal of Urology</i> , <b>2021</b> , 39, 1445-1452	4	
825	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 236.e1-236.e7	2.8	6
824	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. <i>European Urology Oncology</i> , <b>2021</b> , 4, 121-123	6.7	5
823	External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 131.e1-131.e7	2.8	1

822	Re: Thulium Laser Transurethral Vaporesection of the Prostate Versus Transurethral Resection of the Prostate for Men with Lower Urinary Tract Symptoms or Urinary Retention (UNBLOCS): A Randomised Controlled Trial. <i>European Urology</i> , <b>2021</b> , 79, 316-317	10.2	
821	Prognostic factors in patients with small renal masses: a comparison between . <i>Cancer Causes and Control</i> , <b>2021</b> , 32, 119-126	2.8	O
820	Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 1187-1190	3.6	4
819	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 36	9. <del>2</del> 9-36	59 <sup>1</sup> .e17
818	Re: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. <i>BJU International</i> , <b>2021</b> , 127, 746	5.6	
817	A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence. <i>BJU International</i> , <b>2021</b> , 127, 575-584	5.6	4
816	Re: Paolo Afonso de Carvalho, JoB A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. Eur Urol 2020;77:628-35:	10.2	1
815	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 235.e15-235.e21	2.8	3
814	IMAGINE-IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines. <i>European Urology</i> , <b>2021</b> , 79, 173-176	10.2	4
813	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 193-201	6.2	1
812	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 253-260	6.2	6
811	Comparison of Two Methods for Assessing Erectile Function Before Radical Prostatectomy. European Urology Oncology, <b>2021</b> , 4, 323-326	6.7	2
810	Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. <i>European Urology Oncology</i> , <b>2021</b> , 4, 42-48	6.7	15
809	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , <b>2021</b> , 4, 301-304	6.7	1
808	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , <b>2021</b> , 15, 11795549211021667	1.8	1
807	Renal histology across the stages of chronic kidney disease. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 699-707	4.8	4
806	Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center ExperienceSigrid Carlsson, Nicole Benfante, Ricardo Alvim, Daniel D. Sjoberg, Andrew Vickers, Victor E. Reuter, Samson W. Fine, Hebert Alberto Vargas, Michal Wiseman, Maha	2.5	
805	Mamoor, Behfar Ehdaie, Vincent Laudone, Peter Scardino, James Eastham and Karim Touijer 2020; Sex-and age-related differences in the distribution of bladder cancer metastases. <i>Japanese Journal of Clinical Oncology</i> , <b>2021</b> , 51, 976-983	2.8	2

### (2021-2021)

804	Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 2641-2650	7.4	5	
803	Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer. Journal of Nuclear Medicine, <b>2021</b> , 62, 1363-1371	8.9	10	
802	Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3177-3185	4	3	
801	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	3	
800	Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4	
799	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e040531	3	1	
798	Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 186-190	7·5	1	
797	What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?. <i>BJU International</i> , <b>2021</b> , 128, 225-235	5.6	2	
796	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Letter. <i>Journal of Urology</i> , <b>2021</b> , 206, 173	2.5		
795	Unexpected Outcomes of Renal Function after Radical Nephrectomy: Histology Relevance along with Clinical Aspects. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1	
794	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , <b>2021</b> , 206, 69-79	2.5	7	
793	Followup of Men with PI-RADSIA or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter. <i>Journal of Urology</i> , <b>2021</b> , 206, 1335	2.5		
792	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , <b>2021</b> , 80, 149-159	10.2	5	
791	Elective nodal radiotherapy in prostate cancer. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e348-e357	21.7	6	
790	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. <i>World Journal of Urology</i> , <b>2021</b> , 1	4	4	
789	The effect of primary urological cancers on survival in men with secondary prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 1149-1158	4.2	2	
788	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. <i>European Urology</i> , <b>2021</b> , 81, 193-193	10.2	9	
787	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e255-e263	3.3	1	

786	Contemporary Outcomes of Patients With Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gufin: Implications for Clinical Trial Design. Letter. <i>Journal of Urology</i> , <b>2021</b> , 206, 152	28 <sup>2.5</sup>	
785	Dissecting patterns of care in patients with variant histology of bladder cancer and lymph node invasion. <i>Soci</i> 町nternationale Diurologie Journal, <b>2021</b> , 282-298	0.1	
784	An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer. <i>Journal of Urology</i> , <b>2021</b> , 101097JU00000000002205	2.5	0
783	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. <i>Surgical Oncology</i> , <b>2021</b> , 38, 101588	2.5	3
782	Reply by Authors. <i>Journal of Urology</i> , <b>2021</b> , 206, 645	2.5	
781	Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-	6.7	2
780	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , <b>2021</b> , 1	2.8	2
779	Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy. <i>Journal of Urology</i> , <b>2021</b> , 206, 638-645	2.5	1
778	Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. <i>Prostate</i> , <b>2021</b> , 81, 1374-1381	4.2	2
777	Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol 2021;80:567-72. <i>European Urology</i> , <b>2021</b> , 80, e147-e148	10.2	
776	Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 838.	e <i>7</i> -838	.e93
775	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. <i>Minerva Urology and Nephrology</i> , <b>2021</b> , 73, 481-488	2.3	2
774	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. <i>European Urology</i> , <b>2021</b> , 80, 319-322	10.2	5
773	Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. <i>International Journal of Urology</i> , <b>2021</b> , 28, 1247-1252	2.3	3
772	Re: Marra et´al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'. <i>BJU International</i> , <b>2021</b> , 128, 523	5.6	1
771	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. <i>European Urology Focus</i> , <b>2021</b> , 7, 943-946	5.1	О
770	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 734.e11-734.e17	2.8	2
769	Non-muscle-invasive bladder cancer: An overview of potential new treatment options. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 642-663	2.8	6

768	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , <b>2021</b> , 80, 507-515	10.2	2
767	Reply by Authors. <i>Journal of Urology</i> , <b>2021</b> , 206, 969	2.5	
766	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 631-641	2.8	3
765	Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. <i>Journal of Urology</i> , <b>2021</b> , 206, 960-969	2.5	1
764	A mechanistic insight into the anti-metastatic role of the prostate specific antigen. <i>Translational Oncology</i> , <b>2021</b> , 14, 101211	4.9	2
763	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 962-970	4.2	O
762	Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU - YAU Prostate Cancer Working Group multi-institutional study. <i>Central European Journal of Urology</i> , <b>2021</b> , 74, 362-365	0.9	О
761	Laser Lithotripsy: The Importance of Peak Power and Pulse Modulation. <i>European Urology Focus</i> , <b>2021</b> , 7, 22-25	5.1	5
760	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors European Urology Oncology, 2021,	6.7	1
759	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. <i>European Urology Oncology</i> , <b>2020</b> , 4, 1001-1001	6.7	9
75 <sup>8</sup>	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e730-e738	3.3	4
757	Reply to Vincenzo Ficarra, Giuseppe Mucciardi, and Gianluca Giannarini's Letter to the Editor re: Riccardo Campi, Daniele Amparore, Umberto Capitanio, et al. Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19	10.2	1
756	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , <b>2020</b> , 78, 21-28	10.2	141
755	Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. <i>European Urology</i> , <b>2020</b> , 78, 289-290	10.2	O
754	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. <i>European Urology</i> , <b>2020</b> , 78, 155-160	10.2	8
753	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , <b>2020</b> , 17, 351-362	5.5	7
75 <sup>2</sup>	Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. <i>European Urology</i> , <b>2020</b> , 78, 321-326	10.2	9
751	An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. Expert Review of Molecular Diagnostics, 2020, 20, 841-850	3.8	7

75°	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2798-2811	2.2	80
749	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. <i>BJU International</i> , <b>2020</b> , 125, 867-875	5.6	10
748	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , <b>2020</b> , 77, 701-710	10.2	66
747	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 246	5.3	5
746	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 539-548	6.2	14
745	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 506-514	2.8	2
744	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 601.e17-601.e24	1 <sup>2.8</sup>	5
743	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , <b>2020</b> , 34, 600-607	2.7	5
742	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 573-580	6.2	9
741	Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. <i>International Journal of Urology</i> , <b>2020</b> , 27, 402-407	2.3	1
740	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , <b>2020</b> , 78, 661-669	10.2	30
739	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , <b>2020</b> , 78, 779-782	10.2	6
738	ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 78, 452-459	10.2	4
737	Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. <i>Cancer Epidemiology</i> , <b>2020</b> , 67, 101762	2.8	7
736	Re: Aurlie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol 2019;75:826-33: Nodal Recurrence of Prostate Cancer	10.2	
735	Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 121, 1154-1161	2.8	4
734	Re: Ola Bratt, Erik Holmberg, Ove Andril, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). Eur Urol	10.2	
733	2019;76:461-6. European Urology, <b>2020</b> , 77, e136  Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 537-544	2.8	2

#### (2020-2020)

732	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e543-e556	3.3	11
731	Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1. <i>European Radiology</i> , <b>2020</b> , 30, 3383-3392	8	27
730	Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 600.e9-600.e15	2.8	6
729	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , <b>2020</b> , 77, 508-547	10.2	155
728	Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol 2019;76:106-14. <i>European Urology</i> , <b>2020</b> , 77, e107	10.2	
727	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 121, 688-696	2.8	10
726	Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. <i>Kidney and Blood Pressure Research</i> , <b>2020</b> , 45, 166-179	3.1	5
725	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. <i>Cancer Causes and Control</i> , <b>2020</b> , 31, 263-272	2.8	5
724	Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-nalle Urothelial Bladder Cancer Patients. <i>European Urology Oncology</i> , <b>2020</b> , 3, 784-788	6.7	12
723	Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. <i>JAMA Network Open</i> , <b>2020</b> , 3, e201913	10.4	4
722	Rates of other-cause mortality after radical cystectomy are decreasing over time-A population-based analysis over two decades. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 121, 1329-1336	2.8	1
721	Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e517-e522	3.3	4
720	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 1347-1352	3.6	3
719	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , <b>2020</b> , 78, 138-142	10.2	18
718	Comprehensive analysis of in-hospital delirium after major surgical oncology procedures: A population-based study. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E84-E93	1.2	4
717	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study.  Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020,	4.4	1
716	Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2020</b> , 46, 1029-1041	2	2
715	Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Urology</i> , <b>2020</b> , 203, 624	2.5	

714	Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Gufin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. <i>Journal of Urology</i> , <b>2020</b> , 203, 625	2.5	
713	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2020</b> , 43, 880-888	2.7	2
712	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1340-1347	7.3	1
711	Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate CancerO. R. Claros, R. R. Tourinho-Barbosa, A.	2.5	
710	Re: The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate BiopsiesA. Amin, M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick,	2.5	0
709	Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2020</b> , 72, 350-359	4.4	6
708	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and</i>	4.4	2
707	Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 44-51	7.3	6
706	Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL. <i>Nuclear Medicine Communications</i> , <b>2020</b> , 41, 1178-1182	1.6	
705	Reply by Authors. <i>Journal of Urology</i> , <b>2020</b> , 204, 302	2.5	
7°5	Reply by Authors. <i>Journal of Urology</i> , <b>2020</b> , 204, 302  The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 685.e17-685.e25	2.5	1
	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original</i>		1
704	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 685.e17-685.e25  Racial differences in the distribution of bladder cancer metastases: a population-based analysis.	2.8	28
7°4 7°3	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 685.e17-685.e25  Racial differences in the distribution of bladder cancer metastases: a population-based analysis. <i>Central European Journal of Urology</i> , <b>2020</b> , 73, 407-415  Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A	2.8	
7°4 7°3 7°2	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 685.e17-685.e25  Racial differences in the distribution of bladder cancer metastases: a population-based analysis. <i>Central European Journal of Urology</i> , <b>2020</b> , 73, 407-415  Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , <b>2020</b> , 203, 338-343  Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-PSMA and C-Choline	2.8	28
704 703 702 701	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 685.e17-685.e25  Racial differences in the distribution of bladder cancer metastases: a population-based analysis. <i>Central European Journal of Urology</i> , 2020, 73, 407-415  Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , 2020, 203, 338-343  Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-PSMA and C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of</i> The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. <i>Journal</i>	2.8 0.9 2.5	28
7°4 7°3 7°2 7°1 7°°	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 685.e17-685.e25  Racial differences in the distribution of bladder cancer metastases: a population-based analysis. <i>Central European Journal of Urology</i> , <b>2020</b> , 73, 407-415  Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , <b>2020</b> , 203, 338-343  Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-PSMA and C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , <b>2020</b> , 204, 962-968  Prediction nomogram for Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> ,	2.8 0.9 2.5 2.5	28 17 7

696	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , <b>2020</b> , 77, 439-446	10.2	119
695	Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 260-26	58 <sup>.2</sup>	2
694	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. Surgical Oncology, <b>2020</b> , 32, 8-13	2.5	16
693	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 35-44.e1	3.3	2
692	Prevalence, assessment and surgical correction of penile curvature in hypospadias patients treated at one European Referral Center: description of the technique and surgical outcomes. <i>World Journal of Urology</i> , <b>2020</b> , 38, 2041-2048	4	5
691	Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 79.e9-79.e14	2.8	10
690	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 314-321.e1	3.3	3
689	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , <b>2020</b> , 77, 636-643	10.2	48
688	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. <i>European Urology</i> , <b>2020</b> , 77, 576-580	10.2	38
687	Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. <i>World Journal of Urology</i> , <b>2020</b> , 38, 2501-2511	4	5
686	Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e402-e409	3.3	4
685	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. <i>European Urology Oncology</i> , <b>2020</b> , 3, 474-480	6.7	5
684	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , <b>2020</b> , 77, 223-250	10.2	60
683	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 76.e1-76.e9	2.8	10
682	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 117-128.e5	3.3	3
681	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). <i>European Urology Oncology</i> , <b>2020</b> , 4, 971-971	6.7	25
680	Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51. <i>European Urology</i> , <b>2020</b> , 78, e165	10.2	1
679	Reply to Jonathan Aning, Paul McCoubrie, and Jon Oxley's Letter to the Editor re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and	10.2	1

Cancer Patients Undergoing Radical Prostatectomy. Eur Urol 2020;77:733-41. *European Urology*, **2020**, 78, e200

678	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1912-1920	13.4	15
677	Reply to VEane Achard, Alan Dal Pra, and Thomas Zilli's Letter to the Editor re: Carlo A. Bravi, Nicola Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously	10.2	3
676	Extended pelvic lymph-node dissection is independently associated with improved overall survival in patients with prostate cancer at high-risk of lymph-node invasion. <i>BJU International</i> , <b>2020</b> , 125, 756-	758 <sup>6</sup>	5
675	A risk calculator predicting recurrence in lymph node metastatic penile cancer. <i>BJU International</i> , <b>2020</b> , 126, 577-585	5.6	9
674	Bladder cancer incidence rates and trends in young adults aged 20-39 years. <i>Urologic Oncology:</i> Seminars and Original Investigations, <b>2020</b> , 38, 934.e11-934.e19	2.8	1
673	Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 527121	5.3	5
672	Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. <i>European Urology</i> , <b>2020</b> , 78, 583-591	10.2	23
671	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2020</b> , 43, 567-574	2.7	3
670	Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27. <i>European Urology</i> , <b>2020</b> , 78, e192	10.2	0
669	Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?. <i>European Urology Oncology</i> , <b>2020</b> ,	6.7	9
668	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. European Urology	6.7	9
667	Oncology, <b>2020</b> , 3, 739-747 Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysis. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 122, 1506-1513	2.8	
666	An up-to-date catalogue of urinary markers for the management of prostate cancer. <i>Current Opinion in Urology</i> , <b>2020</b> , 30, 684-688	2.8	1
665	Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1638-1639	13.4	1
664	How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?. <i>Frontiers in Surgery</i> , <b>2020</b> , 7, 563006	2.3	9
663	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. Canadian Urological Association Journal, <b>2020</b> , 14, E173-E179	1.2	1
662	Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. <i>European Urology Focus</i> , <b>2020</b> , 6, 298-304	5.1	10
661	Performance of [Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> 2020, 23, 1-10	6.2	18

660	External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. <i>International Urology and Nephrology</i> , <b>2020</b> , 52, 59-66	2.3	3
659	There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. <i>European Urology Oncology</i> , <b>2020</b> , 3, 112-118	6.7	23
658	Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. <i>European Urology Oncology</i> , <b>2020</b> , 3, 631-639	6.7	2
657	Consulting "Dr. Google" for Prostate Cancer Treatment Options: A Contemporary Worldwide Trend Analysis. <i>European Urology Oncology</i> , <b>2020</b> , 3, 481-488	6.7	17
656	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 129-137.e3	3.3	2
655	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 77.e1-77.e7	2.8	9
654	Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. <i>European Urology Oncology</i> , <b>2020</b> , 3, 209-215	6.7	21
653	Does working channel position influence the effectiveness of flexible ureteroscopy? Results from an in vitro study. <i>BJU International</i> , <b>2020</b> , 125, 449-456	5.6	9
652	Diagnostic Value of F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , <b>2020</b> , 3, 73-79	6.7	12
651	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. European	10.2	38
650	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 204-209	2.8	5
649	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 718-723	3.6	11
648	Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. <i>World Journal of Urology</i> , <b>2020</b> , 38, 725-732	4	6
647	How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection. <i>World Journal of Urology</i> , <b>2020</b> , 38, 1229-1233	4	3
646	Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. <i>World Journal of Urology</i> , <b>2020</b> , 38, 1535-1544	4	4
645	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e610-e618	3.3	3
644	Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. <i>European Urology</i> , <b>2020</b> , 78, 11-15	10.2	62
643	Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2020</b> , 19, 31-36	1.7	4

642	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 739-755	3.5	5
641	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. <i>International Urology and Nephrology</i> , <b>2019</b> , 51, 2181-2188	2.3	6
640	Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 13218	4.9	9
639	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. <i>European Urology Oncology</i> , <b>2019</b> , 2, 541-548	6.7	17
638	Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging. <i>International Journal of Urology</i> , <b>2019</b> , 26, 458-464	2.3	8
637	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. <i>BJU International</i> , <b>2019</b> , 124, 35-39	5.6	2
636	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. <i>Urologia Internationalis</i> , <b>2019</b> , 102, 269-276	1.9	4
635	The critical role of lymph node dissection in selecting high-risk nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 293.e25-293.e30	2.8	5
634	Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. <i>Surgical Oncology</i> , <b>2019</b> , 28, 201-207	2.5	10
633	F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
632	Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. <i>BJU International</i> , <b>2019</b> , 124, 100	06 <sup>5</sup> 1013	<b>3</b> 5
631	Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 702-710	2.8	4
630	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , <b>2019</b> , 124, 656	5.6	25
629	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , <b>2019</b> , 76, 142-150	10.2	51
628	Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis. <i>International Journal of Urology</i> , <b>2019</b> , 26, 760-774	2.3	17
627	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 623-631	3.6	9
626	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. <i>Journal of Endourology</i> , <b>2019</b> , 33, 606-613	2.7	10
625	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. <i>BJU International</i> , <b>2019</b> , 124, 738-745	5.6	14

624	The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. <i>World Journal of Urology</i> , <b>2019</b> , 37, 2707-2714	4	1
623	Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 75, 20-26	14.4	15
622	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1557-1570	4	10
621	Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 1942-1949	3.1	7
620	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e602-e611	3.3	9
619	Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. <i>Journal of Endourology</i> , <b>2019</b> , 33, 438-447	2.7	30
618	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , <b>2019</b> , 76, 443-449	10.2	8
617	Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. <i>Cancer Epidemiology</i> , <b>2019</b> , 59, 135-142	2.8	3
616	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 1253-1259	3.6	4
615	Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy. <i>World Journal of Urology</i> , <b>2019</b> , 37, 221-7	234	19
614	Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma. <i>World Journal of Urology</i> , <b>2019</b> , 37, 701-708	4	0
613	Imaging modalities in synchronous oligometastatic prostate cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 2573-2583	4	11
612	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. <i>World Journal of Urology</i> , <b>2019</b> , 37, 243-251	4	25
611	Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. <i>World Journal of Urology</i> , <b>2019</b> , 37, 469-479	4	17
610	Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. Eur Urol 2019;76:284-303. <i>European Urology</i> , <b>2019</b> , 76, e132	10.2	
609	A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 395-401	3.3	8
608	Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. <i>Anticancer Research</i> , <b>2019</b> , 39, 4357-4361	2.3	10
607	Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e1026-e1035	3.3	9

606	Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization. <i>European Journal of Radiology</i> , <b>2019</b> , 118, 51-57	4.7	9
605	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , <b>2019</b> , 76, 425-429	10.2	10
604	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 578.e11-578.e19	2.8	4
603	How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. <i>Urologic Oncology:</i> Seminars and Original Investigations, <b>2019</b> , 37, 893-899	2.8	5
602	Impact of Obesity on Perioperative Outcomes at Robotic-assisted and Open Radical Prostatectomy: Results From the National Inpatient Sample. <i>Urology</i> , <b>2019</b> , 133, 135-144	1.6	12
601	The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1193-1195	21.7	3
600	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , <b>2019</b> , 76, 790-813	10.2	76
599	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e1153-e1162	3.3	6
598	Oncologic outcomes in prostate cancer patients treated with robot-assisted radical prostatectomy: results from a single institution series with more than 10 years follow up. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2019</b> , 71, 38-46	4.4	10
597	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC) Journal of Clinical	2.2	3
596	Prevalence and surgical management of pubic hypertrophy in hypospadias patients: results from a high-volume surgeon. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2019</b> , 45, 1238-1248	2	2
595	Reply by Authors. <i>Journal of Urology</i> , <b>2019</b> , 202, 1181	2.5	
594	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. <i>Journal of Urology</i> , <b>2019</b> , 202, 108-113	2.5	40
593	Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. <i>Journal of Urology</i> , <b>2019</b> , 202, 1174-1181	2.5	25
592	Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. <i>Journal of Urology</i> , <b>2019</b> , 202, 1120-1126	2.5	13
591	Robot-assisted versus open cystectomy in the RAZOR trial. <i>Lancet, The</i> , <b>2019</b> , 393, 645	40	1
590	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. <i>BJU International</i> , <b>2019</b> , 124, 431-440	5.6	48
589	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e541-e548	3.3	3

588	Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. <i>International Journal of Urology</i> , <b>2019</b> , 26, 487-492	2.3	8
587	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , <b>2019</b> , 2, 248-256	6.7	9
586	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. <i>European Urology Oncology</i> , <b>2019</b> , 2, 456-463	6.7	8
585	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. <i>European Urology Oncology</i> , <b>2019</b> , 2, 294-301	6.7	13
584	Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer. <i>Current Opinion in Urology</i> , <b>2019</b> , 29, 629-635	2.8	2
583	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 7-14.e3	3.3	6
582	Nomograms in urologic oncology, advantages and disadvantages. <i>Current Opinion in Urology</i> , <b>2019</b> , 29, 42-51	2.8	16
581	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 123-129	2.8	5
580	What is new in robot-assisted radical prostatectomy: a narrative review. <i>Current Opinion in Urology</i> , <b>2019</b> , 29, 14-18	2.8	4
579	Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 1238-1245	3.6	11
578	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. <i>European Urology</i> , <b>2019</b> , 75, 817-825	10.2	11
577	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1631-1637	4	1
576	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 105-113.e2	3.3	11
575	C-choline PET/CT predicts survival in prostate cancer patients with PSA . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 921-929	8.8	9
574	Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience. <i>European Urology</i> , <b>2019</b> , 75, 871-874	10.2	5
573	Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e97-e103	3.3	5
572	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. <i>European Urology</i> , <b>2019</b> , 75, 506-514	10.2	91
571	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. <i>European Urology</i> , <b>2019</b> , 76, 493-504	10.2	62

570	Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology. <i>Advances in Therapy</i> , <b>2019</b> , 36, 1-18	4.1	8
569	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. <i>Cancer Epidemiology</i> , <b>2019</b> , 58, 83-88	2.8	9
568	Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. <i>Urologia Internationalis</i> , <b>2019</b> , 102, 51-59	1.9	2
567	Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1329-1337	4	4
566	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , <b>2019</b> , 75, 176-183	10.2	60
565	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 72-78.e4	3.3	5
564	Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. <i>BJU International</i> , <b>2019</b> , 123, 646-650	5.6	17
563	The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1127-1135	4	6
562	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 44-60	10.2	29
561	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>European Urology</i> , <b>2019</b> , 75, 319-328	10.2	22
560	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. <i>European Urology Focus</i> , <b>2019</b> , 5, 171-178	5.1	30
559	PD-L1 Expression and CD8 T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , <b>2019</b> , 5, 192-196	5.1	60
558	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2019</b> , 5, 97-103	5.1	2
557	The Association of Uromodulin Genotype with Renal Cancer Aggressiveness. <i>European Urology Focus</i> , <b>2019</b> , 5, 262-265	5.1	3
556	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. <i>European Urology Focus</i> , <b>2019</b> , 5, 381-388	5.1	9
555	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. <i>European Urology Focus</i> , <b>2019</b> , 5, 467-47	7 <b>3</b> .1	10
554	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. <i>European Urology Focus</i> , <b>2019</b> , 5, 545-549	5.1	2
553	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. <i>European Urology Focus</i> , <b>2019</b> , 5, 568-576	5.1	5

552	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. <i>European Urology Focus</i> , <b>2019</b> , 5, 488-496	5.1	25	
551	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. <i>European Urology Focus</i> , <b>2019</b> , 5, 449-456	5.1	8	
550	The effect of race on survival after local therapy in metastatic prostate cancer patients. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 13, 175-181	1.2	1	
549	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , <b>2018</b> , 78, 469-475	4.2	29	
548	Incidental Detection of Basaloid Thymic Carcinoma With Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e497-e499	3.3	2	
547	Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A	10.2		
546	Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 239.e1-239.e7	2.8	21	
545	Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer. <i>BJU International</i> , <b>2018</b> , 122, 1025-1033	5.6	54	
544	Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database. <i>International Journal of Urology</i> , <b>2018</b> , 25, 574-581	2.3	2	
543	Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. <i>Prostate</i> , <b>2018</b> , 78, 753-757	4.2	21	
542	A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 318-325	5.3	11	
541	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 239.e9-239.e15	2.8	4	
540	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 176-183	3.3	10	
539	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. <i>World Journal of Urology</i> , <b>2018</b> , 36, 639-644	4	12	
538	Adherence to the European Association of Urology Guidelines: A National Survey among Italian Urologists. <i>Urologia Internationalis</i> , <b>2018</b> , 100, 139-145	1.9	6	
537	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 425-438	3.8	8	
536	Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. <i>European Radiology</i> , <b>2018</b> , 28, 1969-1976	8	33	
535	Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. <i>Journal of Urology</i> , <b>2018</b> , 199, 1143-1148	2.5	29	

534	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 158.e1-158.e6	2.8	8
533	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 81.e <sup>-2</sup>	2.8 1 <b>7-81.</b> e	10 <b>24</b>
532	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e619-e	6273	2
531	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. <i>Abdominal Radiology</i> , <b>2018</b> , 43, 2391-2399	3	12
530	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1399-1407	4	9
529	Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection. <i>European Urology</i> , <b>2018</b> , 74, 253-256	10.2	32
528	Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1417-1422	4	10
527	The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. <i>European Urology</i> , <b>2018</b> , 74, 4-7	10.2	29
526	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 307.e9-307.e14	2.8	10
525	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. <i>Cell Reports</i> , <b>2018</b> , 22, 3006-3020	10.6	32
524	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , <b>2018</b> , 74, 134-137	10.2	8
523	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1767-1777	59.2	1250
522	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. <i>European Urology Focus</i> , <b>2018</b> , 4, 68-74	5.1	12
521	Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. <i>European Urology Focus</i> , <b>2018</b> , 4, 245-251	5.1	14
520	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. <i>European Urology Focus</i> , <b>2018</b> , 4, 369-375	5.1	8
519	Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. <i>European Urology Focus</i> , <b>2018</b> , 4, 834-841	5.1	6
518	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. <i>European Urology</i> , <b>2018</b> , 73, 890-896	10.2	59
517	Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e451-e467	3.3	11

516	Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer. <i>BJU International</i> , <b>2018</b> , 121, 421-427	5.6	17
515	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , <b>2018</b> , 36, 7-13	4	17
514	Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate	10.2	
513	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , <b>2018</b> , 36, 51-57	4	11
512	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , <b>2018</b> , 121, 383-392	5.6	19
511	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> ,	5.6	41
510	Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. European Urology, 2018, 73, 793-799	10.2	19
509	Depressive Symptoms and Low Sexual Desire after Radical Prostatectomy: Early and Long-Term Outcomes in a Real-Life Setting. <i>Journal of Urology</i> , <b>2018</b> , 199, 474-480	2.5	15
508	Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies	10.2	3
507	(VI-RADS-IO). European Urology, <b>2018</b> , 74, e107-e108  The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma. <i>Frontiers in Surgery</i> , <b>2018</b> , 5, 26	2.3	7
506	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, E325-E330	1.2	11
505	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. <i>European Urology Oncology</i> , <b>2018</b> , 1, 160-168	6.7	12
504	Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. Canadian Urological Association Journal, 2018, 12, E338-E344	1.2	6
503	In-hospital length of stay after major surgical oncological procedures. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 969-974	3.6	24
502	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. <i>Journal of Endourology</i> , <b>2018</b> , 32, 621-629	2.7	7
501	Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. <i>Urology</i> , <b>2018</b> , 122, 152-157	1.6	17
500	Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer. <i>Clinica Chimica Acta</i> , <b>2018</b> , 486, 185-191	6.2	23
499	Effect of the number of removed lymph nodes on prostate cancer recurrence and survival: evidence from an observational study. <i>BMC Bioinformatics</i> , <b>2018</b> , 19, 200	3.6	2

498	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 376-384.e1	3.3	17
497	External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 364.e1-364.e7	2.8	9
496	Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 365.e1-365.e7	2.8	5
495	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. <i>European Urology</i> , <b>2018</b> , 74, 357-368	10.2	72
494	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. European Urology Oncology, <b>2018</b> , 1, 46-53	6.7	26
493	Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of Morbidity, Renal Function, and Oncologic Outcomes. <i>European Urology Oncology</i> , <b>2018</b> , 1, 61-68	6.7	21
492	Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. <i>European Urology Oncology</i> , <b>2018</b> , 1, 29-36	6.7	26
491	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC) <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS534-TPS5	2.2 34	4
490	Erectile Dysfunction and Penile Rehabilitation After Robot-Assisted Radical Prostatectomy <b>2018</b> , 455-4	62	1
489	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC) <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4595-TPS	2.2 4595	0
488	Estimated glomerular filtration rate: Do we measure the real renal function or are we still groping in the dark?. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e18809-e18809	2.2	
487	Oncological and functional outcomes of elderly men treated with HIFU vs. minimally invasive radical prostatectomy: A propensity score analysis. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 185	5-3:91	5
486	Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 100-105	6.2	9
485	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , <b>2018</b> , 73, 512-518	10.2	27
484	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. <i>BJU International</i> , <b>2018</b> , 121, 592-599	5.6	24
483	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. <i>International Urology and Nephrology</i> , <b>2018</b> , 50, 71-	7 <del>8</del> .3	29
482	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , <b>2018</b> , 73, 436-444	10.2	41
481	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3353-3360	2.2	265

480	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. <i>European Urology Oncology</i> , <b>2018</b> , 1, 169-175	6.7	12
479	The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. <i>European Urology Oncology</i> , <b>2018</b> , 1, 215-2	227	10
478	Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 528.e7-528.e13	2.8	3
477	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e696-e708	21.7	59
476	Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell'Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes	10.2	
475	after Robot-assisted Radical Prostatectomy. Eur Urol 2018;74:4-7. European Urology, 2018, 74, e116-e17 Combining anticancer drugs with osteoprotective agents in prostate cancer-A contemporary update. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 488-497	2.8	
474	Techniques to Improve Sexual Function Following Robot-Assisted Radical Prostatectomy <b>2018</b> , 401-407	•	
473	Pelvic Lymph Node Dissection for Prostate Cancer and Nomograms <b>2018</b> , 317-330		
472	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 529.6	27 <sup>8</sup> -52	9.e22
471	Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages IT1b: a single institution, matched analysis. <i>Central European Journal of Urology</i> , <b>2018</b> , 71, 48-57	0.9	1
470	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , <b>2018</b> , 56, 118-125	2.8	9
469	How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , <b>2018</b> , 122, 823-830	5.6	13
468	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , <b>2018</b> , 54, 112-	178	8
467	Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. <i>Journal of Endourology</i> , <b>2018</b> , 32, 701-709	2.7	9
466	Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. <i>European Urology Oncology</i> , <b>2018</b> , 1, 120-128	6.7	37
465	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. <i>European Urology Oncology</i> , <b>2018</b> , 1, 314-320	6.7	11
464	Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. <i>European Urology Oncology</i> , <b>2018</b> , 1, 346-351	6.7	4
463	Pathological High-risk Renal Cell Carcinoma: Trends in Clinical Characteristics Over 25 Years. <i>Anticancer Research</i> , <b>2018</b> , 38, 4123-4130	2.3	6

462	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. <i>Nature</i> , <b>2018</b> , 559, 363-369	50.4	163
461	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. <i>World Journal of Urology</i> , <b>2017</b> , 35, 517-526	4	9
460	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , <b>2017</b> , 35, 251-259	4	16
459	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. <i>BJU International</i> , <b>2017</b> , 119, 234-238	5.6	11
458	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , <b>2017</b> , 35, 113-120	4	15
457	Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 249-256	10.2	50
456	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , <b>2017</b> , 35, 121-130	4	25
455	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. <i>European Urology</i> , <b>2017</b> , 71, 648-655	10.2	132
454	North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. <i>Prostate</i> , <b>2017</b> , 77, 542-548	4.2	13
453	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e603-e607	3.3	20
452	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 335-3	3 <b>41</b> <sup>8</sup>	45
45 <sup>1</sup>	Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 469-470	2.2	3
450	Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol 2017;72:289-92. Do the Data Violate	10.2	2
449	Kaplan-Meier Assumptions?. European Urology, 2017, 72, e31 Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e681-e688	3.3	8
448	Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. <i>European Urology</i> , <b>2017</b> , 72, 689-709	10.2	57
447	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , <b>2017</b> , 35, 1541-1547	4	27
446	The Microbiome of the Prostate Tumor Microenvironment. <i>European Urology</i> , <b>2017</b> , 72, 625-631	10.2	100
445	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 72, 632-640	10.2	93

444	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 528.e1-528.e5	2.8	10	
443	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 460.e1-460	).e8	7	
442	Diagnostic Accuracy of Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. <i>Urology</i> , <b>2017</b> , 106, 139-145	1.6	34	
441	Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e793-e800	3.3	30	
440	Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer. <i>Urology</i> , <b>2017</b> , 102, 130-137	1.6	9	
439	Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 113.e9-113.e14	2.8	5	
438	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>European Urology</i> , <b>2017</b> , 72, 910-917	10.2	17	
437	The role of prostatic inflammation in the development and progression of benign and malignant diseases. <i>Current Opinion in Urology</i> , <b>2017</b> , 27, 99-106	2.8	34	
436	Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer. <i>Current Urology Reports</i> , <b>2017</b> , 18, 51	2.9	10	
435	Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 461.e7-461.e14	2.8	14	
434	External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. <i>Prostate</i> , <b>2017</b> , 77, 928-933	4.2	7	
433	An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. <i>Urology Case Reports</i> , <b>2017</b> , 12, 34-36	0.5	3	
432	Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 264-271	2.8	15	
431	Local Therapy Improves Survival in Metastatic Prostate Cancer. European Urology, 2017, 72, 118-124	10.2	77	
430	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e755-e764	3.3	24	
429	Re: Low Adherence to Guidelines in Nonmuscle-invasive Disease. <i>European Urology</i> , <b>2017</b> , 71, 689	10.2	1	
428	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 151.e17-151.e23	2.8	13	
427	Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 150, e9-150, e15	2.8	29	

426	Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. <i>Minerva Urology and Nephrology</i> , <b>2017</b> , 69, 173-180	2.3	4
425	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1982-1990	2.2	56
424	Screening and Treating Prostate Cancer in the Older Patient: Decision Making Across the Clinical Spectrum. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 370-381	7.1	2
423	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	9
422	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	7
421	External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	1
420	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T N M renal cell carcinoma. <i>World Journal of Urology</i> , <b>2017</b> , 35, 1899-1905	4	19
419	New surgical approaches for clinically high-risk or metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 1013-1031	3.5	5
418	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 672.e1-672.e6	2.8	3
417	When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging: Indications for Preoperative Bone Scintigraphy. <i>Urology</i> , <b>2017</b> , 110, 114-120	1.6	5
416	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , <b>2017</b> , 49, 2143-2149	2.3	25
415	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e1039-e1045	3.3	7
414	Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. <i>Journal of Endourology</i> , <b>2017</b> , 31, 872-87	<b>·</b> <del>?</del> ·7	30
413	Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 659.e7-659.e12	2.8	
412	Salvage surgery for nodal recurrent prostate cancer. Current Opinion in Urology, 2017, 27, 604-611	2.8	8
411	Lymph node dissection should not be dismissed in case of localized renal cell carcinoma in the presence of larger diseases. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 662.e9-66	2:8 2:e15	7
410	Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. <i>BJU International</i> , <b>2017</b> , 120, 69-75	5.6	8
409	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study. <i>Prostate</i> , <b>2017</b> , 77, 263-273	4.2	18

408	When to perform preoperative chest computed tomography for renal cancer staging. <i>BJU International</i> , <b>2017</b> , 120, 490-496	5.6	4
407	Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. <i>Prostate</i> , <b>2017</b> , 77, 234-241	4.2	4
406	Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. <i>Prostate</i> , <b>2017</b> , 77, 105-113	4.2	20
405	Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Prostate</i> , <b>2017</b> , 77, 3-9	4.2	7
404	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , <b>2017</b> , 71, 886-893	10.2	61
403	Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. <i>European Urology</i> , <b>2017</b> , 72, 289-292	10.2	56
402	Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 72, 432-438	10.2	32
401	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e223-e228	3.3	4
400	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. <i>Journal of Urology</i> , <b>2017</b> , 197, 669-675	2.5	39
399	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 67-71	3.3	12
398	Re: Family History and Probability of Prostate Cancer, Differentiated by Risk Category - A Nationwide Population-based Study. <i>European Urology</i> , <b>2017</b> , 71, 143-144	10.2	2
397	Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. <i>International Journal of Urology</i> , <b>2017</b> , 24, 117-123	2.3	12
396	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , <b>2017</b> , 35, 1073-1080	4	8
395	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e267-e	2 <del>7</del> 3	25
394	Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. <i>Urologia</i> , <b>2017</b> , 84, 9-19	1.2	20
393	Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. <i>Biomedicine Hub</i> , <b>2017</b> , 2, 162-168	1.3	O
392	Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical Cystectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 327-333	7.3	16
391	Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. European Urology, <b>2016</b> , 69, 193-6	10.2	25

390	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 57.e1-7	2.8	20
389	Dismiss Systematic Transrectal Ultrasound-guided and Embrace Targeted Magnetic Resonance Imaging-informed Prostate Biopsy: Is the Paradigm Ready to Shift?. <i>European Urology</i> , <b>2016</b> , 69, 381-3	10.2	5
388	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , <b>2016</b> , 69, 186-90	10.2	13
387	Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. <i>BJU International</i> , <b>2016</b> , 117, 604-10	5.6	49
386	Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database. <i>International Journal of Urology</i> , <b>2016</b> , 23, 1000-1008	2.3	7
385	Salvage radiotherapy for patients with rising PSA. Lancet Oncology, The, 2016, 17, e314-e315	21.7	
384	The Effect of Obesity on Perioperative Outcomes Following Percutaneous Nephrolithotomy. Journal of Endourology, <b>2016</b> , 30, 864-70	2.7	6
383	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 1343-1350	8.7	20
382	Rationale for local treatment in the management of metastatic prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , <b>2016</b> , 10, 266-72	2.6	5
381	Effectiveness of a Combination of Cranberries, Lactobacillus rhamnosus, and Vitamin C for the Management of Recurrent Urinary Tract Infections in Women: Results of a Pilot Study. <i>European Urology</i> , <b>2016</b> , 70, 912-915	10.2	16
380	Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1661-1670	4.1	15
379	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, 669-78	1.1	9
378	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , <b>2016</b> , 2, 79-85	5.1	29
377	Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. <i>European Urology Focus</i> , <b>2016</b> , 2, 514-521	5.1	8
376	Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol 2016;70:588-96: Testing the Utility of Genomic Scores in the Setting of	10.2	1
375	Recurrent Prostate Cancer After Radical Prostatectomy: We Can Certainly Do Better. European Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. World Journal of Urology, 2016, 34, 1429-36	4	12
374	A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. <i>European Urology</i> , <b>2016</b> , 69, 788-	- <b>5</b> 4·2	99
373	Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 118, 79-84	5.3	42

### (2016-2016)

372	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. <i>Urology</i> , <b>2016</b> , 88, 97-103	1.6	10
371	Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e177-82	3.3	7
370	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 233.e1-6	2.8	19
369	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e341-6	3.3	9
368	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. <i>European Urology Focus</i> , <b>2016</b> , 2, 86-91	5.1	12
367	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 433-40	3.5	16
366	Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: Development and external validation of a nomogram of clinical use. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 291.e9-291.e17	2.8	19
365	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 256.e7-256.e13	2.8	15
364	Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. <i>Insights Into Imaging</i> , <b>2016</b> , 7, 205-14	5.6	36
363	New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>European Urology</i> , <b>2016</b> , 70, 161-175	10.2	154
362	Diagnostic and Therapeutic Implications of Erectile Dysfunction in Patients with Cardiovascular Disease. <i>European Urology</i> , <b>2016</b> , 70, 219-22	10.2	19
361	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , <b>2016</b> , 34, 1411-9	4	7
360	Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1704-5	2.2	1
359	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4. <i>European Urology</i> , <b>2016</b> , 70, e72-4	10.2	5
358	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. <i>European Urology</i> , <b>2016</b> , 70, 429-35	10.2	9
357	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , <b>2016</b> , 34, 1155-61	4	4
356	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. <i>European Urology</i> , <b>2016</b> , 69, 1142-8	10.2	38
355	Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e245-50	3.3	4

354	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. <i>European Journal of Cancer</i> , <b>2016</b> , 54, 27-34	7.5	25
353	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 234.e13-9	2.8	13
352	Words of Wisdom. Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 69, 370	10.2	
351	Orgasmic Dysfunction After Robot-assisted Versus Open Radical Prostatectomy. <i>European Urology</i> , <b>2016</b> , 70, 223-6	10.2	30
350	A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. <i>World Journal of Urology</i> , <b>2016</b> , 34, 207-13	4	10
349	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 59.e15-22	2.8	14
348	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , <b>2016</b> , 69, 728-733	10.2	78
347	Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: A Population-based Study. <i>Urology</i> , <b>2016</b> , 89, 63-7	1.6	12
346	The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2016</b> , 16, 1444-1449	3.2	4
345	Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. <i>Translational Andrology and Urology</i> , <b>2016</b> , 5, 720-734	2.3	11
344	Postprostatectomy Erectile Dysfunction: A Review. World Journal of Men?s Health, 2016, 34, 73-88	6.8	35
343	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>Frontiers in Surgery</i> , <b>2016</b> , 3, 65	2.3	13
342	The Authors Respond. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 117-22	7.3	
341	Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. <i>BJU International</i> , <b>2016</b> , 117, 740-7	5.6	22
340	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. <i>BJU International</i> , <b>2016</b> , 118, 243-9	5.6	11
339	Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. <i>BJU International</i> , <b>2016</b> , 118, 541-6	5.6	11
338	When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database. <i>Journal of Endourology</i> , <b>2016</b> , 30, 201-7	2.7	10
337	Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. <i>Journal of Urology</i> , <b>2016</b> , 196, 1008-13	2.5	40

336	Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 1037-1045	4	18
335	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3. <i>European Urology</i> , <b>2016</b> , 70, e69-70	10.2	
334	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30. <i>European Urology</i> , <b>2016</b> , 70, e15-e16	10.2	4
333	Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. <i>World Journal of Urology</i> , <b>2016</b> , 34, 1357-66	4	7
332	Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. <i>World Journal of Urology</i> , <b>2016</b> , 34, 1139-45	4	12
331	Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?. <i>Journal of Endourology</i> , <b>2016</b> , 30, 400-5	2.7	11
330	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in <b>P</b> T2, pN0 Patients With a Comprehensive Tumor Control Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 333-340	4	11
329	STAMPEDE trial and patients with non-metastatic prostate cancer. <i>Lancet, The</i> , <b>2016</b> , 388, 234-5	40	3
328	The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 471-9	5.5	57
327	Timing of androgen-deprivation therapy for prostate cancer: still a long way to go. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e313	21.7	1
326	The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Gufin. <i>BJU International</i> , <b>2016</b> , 118, 44-52	5.6	72
325	The oncologic role of local treatment in primary metastatic prostate cancer. <i>World Journal of Urology</i> , <b>2015</b> , 33, 755-61	4	9
324	[IIC]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 877-84	8.8	35
323	Reply to Jovo Bogdanoviland Vuk Sekuliß Letter to the Editor re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212-9. <i>European Urology</i> , <b>2015</b> , 68, e3	10.2 37-8	1
322	Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. <i>Journal of Urology</i> , <b>2015</b> , 194, 983-8	2.5	60
321	Words of wisdom. Re: Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. <i>European Urology</i> , <b>2015</b> , 67, 974-5	10.2	2
320	Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. <i>European Urology</i> , <b>2015</b> , 68, 497-505	10.2	63
319	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>European Urology</i> , <b>2015</b> , 68, 949-56	10.2	37

318	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 71.e21-6	2.8	26
317	What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 164.e1-9	2.8	26
316	Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 71.e1-9	2.8	55
315	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. <i>European Urology</i> , <b>2015</b> , 68, 777-84	10.2	41
314	A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , <b>2015</b> , 68, 750-3	10.2	28
313	Erectile Dysfunction in Coronary Artery Disease and Heart Failure <b>2015</b> , 59-71		2
312	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. <i>European Urology Focus</i> , <b>2015</b> , 1, 173-184	5.1	10
311	Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. <i>International Journal of Urology</i> , <b>2015</b> , 22, 89-95	2.3	20
310	The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. <i>Current Oncology Reports</i> , <b>2015</b> , 17, 53	6.3	6
309	A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2345-67	7.5	57
308	Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Gr\u00edberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. Eur Urol 2015;67:819-22. <i>European Urology</i> , <b>2015</b> , 68, e134-5	10.2	3
307	Reply to C.G. Rusthoven et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1989	2.2	1
306	Re: Alessandro Volpe, Kamran Ahmed, Prokar Dasgupta, et al. Pilot Validation Study of the European Association of Urology Robotic Training Curriculum. Eur Urol 2015;68:292-9. <i>European Urology</i> , <b>2015</b> , 68, e29-30	10.2	1
305	Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics. <i>European Urology Focus</i> , <b>2015</b> , 1, 191-199	5.1	5
304	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1165-71	4	15
303	Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. <i>European Urology</i> , <b>2015</b> , 67, 3-6	10.2	95
302	Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. <i>European Urology</i> , <b>2015</b> , 67, 157-164	10.2	133
301	Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. <i>European Urology</i> , <b>2015</b> , 67, 319-25	10.2	11

## (2015-2015)

300	Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. <i>European Urology</i> , <b>2015</b> , 67, 839-49	10.2	63
299	Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. <i>European Urology</i> , <b>2015</b> , 67, 299-309	10.2	158
298	More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. <i>European Urology</i> , <b>2015</b> , 67, 212-9	10.2	134
297	Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients. <i>BJU International</i> , <b>2015</b> , 115, 722-7	5.6	18
296	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , <b>2015</b> , 116, 72-8	5.6	26
295	Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review. <i>International Journal of Urology</i> , <b>2015</b> , 22, 22-32	2.3	44
294	Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. <i>European Urology</i> , <b>2015</b> , 67, 619-26	10.2	102
293	Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. <i>European Urology</i> , <b>2015</b> , 67, 852-63	10.2	237
292	What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer?. <i>European Urology</i> , <b>2015</b> , 67, 597-8	10.2	16
291	Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. <i>European Urology</i> , <b>2015</b> , 68, 325-34	10.2	175
290	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 265.e1-7	2.8	11
289	Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. <i>BJU International</i> , <b>2015</b> , 115, 571-9	5.6	25
288	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gufin: results of a retrospective multicenter study of 2451 patients. <i>European Urology</i> , <b>2015</b> , 67, 74-82	10.2	149
287	Re: epithelial-to-mesenchymal transition in renal neoplasms. <i>European Urology</i> , <b>2015</b> , 68, 736-7	10.2	8
286	Expression-profiling of apoptosis induced by ablation of the long ncRNA TRPM2-AS in prostate cancer cell. <i>Genomics Data</i> , <b>2015</b> , 3, 4-5		17
285	Case Presentation: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking. <i>European Urology Focus</i> , <b>2015</b> , 1, 90-91	5.1	
284	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1351-8	7.3	15
283	Case Presentation: Intermediate-risk Prostate Cancer in a Fit 66-year-old Man. <i>European Urology Focus</i> , <b>2015</b> , 1, 207-208	5.1	

282	Long-term outcomes of robot-assisted radical prostatectomy: Where do we stand?. <i>BJU International</i> , <b>2015</b> , 116, 845-6	5.6	
281	Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. <i>International Journal of Urology</i> , <b>2015</b> , 22, 555-61	2.3	11
280	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. <i>Prostate</i> , <b>2015</b> , 75, 1484-91	4.2	19
279	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. <i>BJU International</i> , <b>2015</b> , 116, 366-72	5.6	3
278	Survivorship and improving quality of life in men with prostate cancer. European Urology, 2015, 68, 374-	· <b>8</b> β0.2	65
277	Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2831-2	2.2	2
276	Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 562-7	3.3	31
275	Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e123-30	3.3	29
274	RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	
273	Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 384.e1-8	2.8	5
272	Reply to Berardino De Bari, Stefano Arcangeli, and Filippo Alongi's letter to the editor re: Nazareno Suardi, Andrea Gallina, Giuliana Lista, et al. impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol 2014;65:546-51. European Urology, 2015,	10.2	
271	67, e27-8 Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2. <i>European Urology</i> , <b>2015</b> , 67, e56-7	10.2	2
270	Defining a standard set of patient-centered outcomes for men with localized prostate cancer. <i>European Urology</i> , <b>2015</b> , 67, 460-7	10.2	136
269	Natural history of surgically treated high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 163.e7-13	2.8	77
268	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. <i>European Urology</i> , <b>2015</b> , 68, 1045-53	10.2	537
267	Prevention and management of post prostatectomy erectile dysfunction. <i>Translational Andrology and Urology</i> , <b>2015</b> , 4, 421-37	2.3	17
266	Penile rehabilitation after radical prostatectomy: does it work?. <i>Translational Andrology and Urology</i> , <b>2015</b> , 4, 110-23	2.3	24
265	Node-positive prostate cancer: a call for level 1 evidence. <i>Oncology</i> , <b>2015</b> , 29, 118, 125, 141	1.8	2

264	Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. <i>European Urology</i> , <b>2014</b> , 66, 1125-32	10.2	21
263	Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study. <i>World Journal of Urology</i> , <b>2014</b> , 32, 559-64	ı <sup>4</sup>	18
262	A systematic review of the association between erectile dysfunction and cardiovascular disease. <i>European Urology</i> , <b>2014</b> , 65, 968-78	10.2	267
261	Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. <i>European Urology</i> , <b>2014</b> , 65, 546-51	10.2	68
260	Early salvage radiotherapy following radical prostatectomy. <i>European Urology</i> , <b>2014</b> , 65, 1034-43	10.2	128
259	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. <i>Urologic Oncology: Seminars and Original</i>	2.8	20
258	Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. <i>Prostate</i> , <b>2014</b> , 74, 210-6	4.2	208
257	The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study. <i>European Urology</i> , <b>2014</b> , 66, 561-8	10.2	52
256	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis. <i>BJU International</i> , <b>2014</b> , 114, E62-E69	5.6	14
255	Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. <i>European Urology</i> , <b>2014</b> , 66, 1024-30	10.2	70
254	Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution	10.2	
253	analysis of 1176 patients. Eur urol 2014;66:1024-30. European Urology, <b>2014</b> , 66, e113-4 Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. European Journal of Pharmacology, <b>2014</b> , 744, 42-51	5.3	12
252	Reply to Christopher Chee Kong Ho, Siew Eng Ho, Srijit Das' letter to the editor re: Giorgio Gandaglia, Alberto Briganti, Graham Jackson, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014;65:968-78. European Urology, <b>2014</b> ,	10.2	2
251	The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.  Urology, 2014, 84, 634-41	1.6	6
250	Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments. <i>Journal of Endourology</i> , <b>2014</b> , 28, 784-91	2.7	36
249	How to optimize patient selection for robot-assisted radical prostatectomy: functional outcome analyses from a tertiary referral center. <i>Journal of Endourology</i> , <b>2014</b> , 28, 792-800	2.7	19
248	Random biopsy: when, how many and where to take the cores?. World Journal of Urology, 2014, 32, 859-	-69	24
247	11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 233-41	8.9	71

246	Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?. Journal of Clinical Oncology, <b>2014</b> , 32, 1299-301	2.2	27
245	Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool. <i>European Urology</i> , <b>2014</b> , 66, 439-46	10.2	18
244	Metabolic syndrome, obesity, and radical cystectomy complications: a clavien classification system-based analysis. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 384-93	3.3	14
243	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 47.e1-8	2.8	7
242	Reply to E. David Crawford and Bo-Eric Persson's letter to the editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026. European	10.2	1
241	Urology, <b>2014</b> , 66, e36-7  A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.  Urologic Oncology: Seminars and Original Investigations, <b>2014</b> , 32, 46.e1-7	2.8	18
240	Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. <i>European Urology</i> , <b>2014</b> , 66, 479-86	10.2	94
239	The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. <i>European Urology</i> , <b>2014</b> , 66, 191-9	10.2	76
238	Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, E148-58	1.2	22
237	External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. <i>Journal of Endourology</i> , <b>2014</b> , 28, 416-23	2.7	29
236	Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>BJU International</i> , <b>2014</b> , 113, 393-8	5.6	48
235	Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). <i>BJU International</i> , <b>2014</b> , 114, 210-5	5.6	51
234	Survival after nephroureterectomy for upper tract urothelial carcinoma: a population-based competing-risks analysis. <i>International Journal of Urology</i> , <b>2014</b> , 21, 249-56	2.3	17
233	Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3939-47	2.2	184
232	Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. <i>BJU International</i> , <b>2014</b> , 114, 503-10	5.6	24
231	Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score. <i>BJU International</i> , <b>2014</b> , 113, 399-407	5.6	18
230	Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , <b>2014</b> , 9, 190	3	6
229	Reply to M. Valerio et al. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3681-2	2.2	

228	Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 748	27.4	1
227	Predicting the risk of bone metastasis in prostate cancer. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 3-11	14.4	43
226	Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 38.e9-16	2.8	54
225	Salvage therapy of small volume prostate cancer nodal failures: a review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 90, 24-35	7	22
224	Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. <i>European Urology</i> , <b>2014</b> , 65, 7-16	10.2	135
223	Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions. <i>European Urology</i> , <b>2014</b> , 66, 635-43	10.2	38
222	Predicting survival of patients with node-positive prostate cancer following multimodal treatment. <i>European Urology</i> , <b>2014</b> , 65, 554-62	10.2	61
221	Re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22,393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol. In press.	10.2	O
220	Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. <i>European Urology</i> , <b>2014</b> , 65, 303-13	10.2	229
219	The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. <i>BJU International</i> , <b>2014</b> , 114, E82-E89	5.6	66
218	Using adjuvant radiotherapy to improve cancer-specific survival in patients with highly aggressive prostate cancer: Examining recently released criteria <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 30-30	2.2	
217	The effect of pathologic T-stage and Gleason score on cancer-specific survival for specimen-confined high-risk prostate cancer <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 114-114	2.2	
216	The effect of pathologic T-stage and Gleason score on cancer-specific survival in patients with positive surgical margins after surgery for high-risk prostate cancer <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 140-140	2.2	
215	Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. <i>Anticancer Research</i> , <b>2014</b> , 34, 3225-30	2.3	31
214	External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. <i>Prostate</i> , <b>2013</b> , 73, 211-8	4.2	45
213	Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. <i>BJU International</i> , <b>2013</b> , 111, 723-30	5.6	20
212	Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis. <i>BJU International</i> , <b>2013</b> , 111, 412-8	5.6	15
211	Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. <i>BJU International</i> , <b>2013</b> , 111, 717-22	5.6	73

210	Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. <i>BJU International</i> , <b>2013</b> , 111, E283-9	5.6	26
209	Erectile dysfunction as a cardiovascular risk factor in patients with diabetes. <i>Endocrine</i> , <b>2013</b> , 43, 285-92	4	29
208	When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up. <i>BJU International</i> , <b>2013</b> , 112, E59-66	5.6	35
207	Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. <i>World Journal of Urology</i> , <b>2013</b> , 31, 275-80	4	25
206	Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines. <i>International Journal of Urology</i> , <b>2013</b> , 20, 405-10	2.3	18
205	Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.  International Journal of Radiation Oncology Biology Physics, 2013, 87, 960-7	4	12
204	Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. <i>European Urology</i> , <b>2013</b> , 63, 693-701	10.2	78
203	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 211-6	5-3	15
202	Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. <i>European Urology</i> , <b>2013</b> , 63, 201-9	10.2	96
<b>2</b> 01	Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder	10.2	
200	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. <i>International Journal of Urology</i> , <b>2013</b> , 20, 413-9	2.3	17
199	The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer. <i>Journal of Urology</i> , <b>2013</b> , 189, 854-9	2.5	11
198	772 SALVAGE LYMPH NODE DISSECTION FOR PATIENTS TREATED WITH RADICAL PROSTATECTOMY WITH BIOCHEMICAL RECURRENCE AND IMAGING-DETECTED NODAL METASTASES. <i>Journal of Urology</i> , <b>2013</b> , 189,	2.5	1
197	Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. <i>European Urology</i> , <b>2013</b> , 64, 557-64	10.2	33
196	1838 WHEN TO PERFORM LYMPH NODE DISSECTION IN RENAL CELL CARCINOMA PATIENTS: A NOVEL APPROACH TO PREOPERATIVELY ASSESS THE RISK OF LYMPH NODE INVASION AT SURGERY AND NODAL PROGRESSION DURING FOLLOW UP. <i>Journal of Urology</i> , <b>2013</b> , 189,	2.5	1
195	Reply to Emily Vertosick and Andrew Vickers' letter to the editor re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. early salvage radiation therapy does not compromise cancer control in patients with pT3N0 Prostate cancer after radical prostatectomy: results of a match-controlled	10.2	
194	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1497-503	2.8	11
193	Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. <i>European Urology</i> , <b>2013</b> , 63, 998-1008	10.2	88

### (2012-2013)

192	Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's letter to the editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol	10.2	1
191	2013;63:998-1008. European Urology, <b>2013</b> , 64, e103-4 Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiology, <b>2013</b> , 37, 219-25	2.8	178
190	Circulating sex steroids and prostate cancer: introducing the time-dependency theory. <i>World Journal of Urology</i> , <b>2013</b> , 31, 267-73	4	5
189	The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). <i>BJU International</i> , <b>2013</b> , 112, 432-41	5.6	156
188	[11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. <i>Journal of Urology</i> , <b>2013</b> , 189, 105-10	2.5	36
187	Results of surgery for high-risk prostate cancer. Current Opinion in Urology, 2013, 23, 342-8	2.8	18
186	Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. <i>BJU International</i> , <b>2013</b> , 111, 1222-30	5.6	28
185	A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. <i>BJU International</i> , <b>2013</b> , 111, 905-13	5.6	13
184	Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy. <i>International Journal of Urology</i> , <b>2013</b> , 20, 572-9	2.3	19
183	Response to Re: Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. <i>International Journal of Urology</i> , <b>2013</b> , 20, 845-6	2.3	1
182	One patient out of four with newly diagnosed erectile dysfunction is a young manworrisome picture from the everyday clinical practice. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1833-41	1.1	79
181	Response to Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. <i>International Journal of Urology</i> , <b>2013</b> , 20, 548-9	2.3	
180	Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance. <i>BJU International</i> , <b>2013</b> , 112, E234-42	5.6	1
179	Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. <i>European Urology</i> , <b>2012</b> , 61, 443-51	10.2	84
178	Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. <i>European Urology</i> , <b>2012</b> , 61, 480-7	10.2	425
177	Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. <i>European Urology</i> , <b>2012</b> , 61, 1132-8	10.2	95
176	Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification. <i>European Urology</i> , <b>2012</b> , 61, 541-8	10.2	65
175	Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. <i>European Urology</i> , <b>2012</b> , 61, 584-92	10.2	94

174	A non-cancer-related survival benefit is associated with partial nephrectomy. <i>European Urology</i> , <b>2012</b> , 61, 725-31	10.2	95
173	High-risk prostate cancer: from definition to contemporary management. <i>European Urology</i> , <b>2012</b> , 61, 1096-106	10.2	101
172	Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. <i>European Urology</i> , <b>2012</b> , 62, 42-52	10.2	54
171	Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 608-17	1.1	29
170	Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated?. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 903-8	1.1	29
169	Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2961-9	1.1	25
168	Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2187-94	1.1	17
167	Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. <i>International Journal of Urology</i> , <b>2012</b> , 19, 836-44	1 <sup>2.3</sup>	76
166	Influence of obesity on tumour volume in patients with prostate cancer. <i>BJU International</i> , <b>2012</b> , 109, 678-84	5.6	22
165	A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy. <i>BJU International</i> , <b>2012</b> , 109, 117	7 <sup>5</sup> 82	11
164	Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. <i>BJU International</i> , <b>2012</b> , 110, E64-8	5.6	27
163	Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. <i>Cancer</i> , <b>2012</b> , 118, 973-80	6.4	22
162	Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2708-15	1.1	69
161	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. <i>World Journal of Urology</i> , <b>2012</b> , 30, 533-9	4	6
160	Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. <i>European Urology</i> , <b>2012</b> , 62, 472-87	10.2	129
159	Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. <i>European Urology</i> , <b>2012</b> , 62, 797-802	10.2	26
158	Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 191-9	4	58
157	Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 624-9	4	20

156	High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 960-5	4	33	
155	Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 84, 95-103	4	21	
154	In reply to Yu. International Journal of Radiation Oncology Biology Physics, 2012, 84, 301-2	4		
153	Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. <i>Journal of Urology</i> , <b>2012</b> , 187, 569-74	2.5	30	
152	Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. <i>Journal of Urology</i> , <b>2012</b> , 188, 84-90	2.5	16	
151	Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. <i>Journal of Urology</i> , <b>2012</b> , 188, 73-83	2.5	35	
150	Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. <i>Urology</i> , <b>2012</b> , 79, 546-51	1.6	32	
149	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1503-11	7.5	39	
148	Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 eraan ecological study. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 3239-46	1.1	16	
147	National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer. <i>Journal of Urology</i> , <b>2012</b> , 188, 423-8	2.5	19	
146	The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma. <i>Urologia</i> , <b>2012</b> , 79, 109-15	1.2	17	
145	Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. <i>Prostate</i> , <b>2012</b> , 72, 186-92	4.2	58	
144	Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. <i>Prostate</i> , <b>2012</b> , 72, 499-506	4.2	10	
143	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies. <i>Prostate</i> , <b>2012</b> , 72, 925-30	4.2	11	
142	Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. <i>International Journal of Urology</i> , <b>2012</b> , 19, 645-51	2.3	45	
141	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , <b>2012</b> , 4, 347-65	3.2	12	
140	Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3648-57	12.9	53	
139	Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. <i>Advances in Urology</i> , <b>2012</b> , 2012, 983058	1.6	10	

138	Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. <i>Clinical Nuclear Medicine</i> , <b>2012</b> , 37, 325-31	1.7	37
137	Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. <i>Canadian Urological Association Journal</i> , <b>2012</b> , 6, 245-50	1.2	15
136	Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate?. <i>Urology</i> , <b>2011</b> , 77, 921-5	1.6	73
135	Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. <i>Urology</i> , <b>2011</b> , 78, 1363-7	1.6	15
134	Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. <i>Korean Journal of Urology</i> , <b>2011</b> , 52, 507-16		38
133	Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence. <i>Current Opinion in Urology</i> , <b>2011</b> , 21, 237-40	2.8	11
132	How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. <i>BJU International</i> , <b>2011</b> , 107, 1095-1	0 <sup>5</sup> 1.6	42
131	Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. <i>BJU International</i> , <b>2011</b> , 107, 1243-9	5.6	11
130	The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. <i>BJU International</i> , <b>2011</b> , 108, 366-71	5.6	29
129	Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. <i>BJU International</i> , <b>2011</b> , 108, 1769-75	5.6	18
128	When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy?. <i>International Journal of Urology</i> , <b>2011</b> , 18, 148-53	2.3	17
127	Factors predicting continence recovery 1 month after radical prostatectomy: results of a multicenter survey. <i>International Journal of Urology</i> , <b>2011</b> , 18, 700-8	2.3	33
126	What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy?. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 1210-7	1.1	32
125	Patients' desire to preserve sexual activity and final decision for a nerve-sparing approach: results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 1495-502	1.1	8
124	The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. <i>European Urology</i> , <b>2011</b> , 59, 51-60	10.2	157
123	A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. <i>European Urology</i> , <b>2011</b> , 59, 88-95	10.2	136
122	Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. <i>European Urology</i> , <b>2011</b> , 59, 832-40	10.2	141
121	Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. <i>European Urology</i> , <b>2011</b> , 60, 205-10	10.2	140

### (2009-2011)

120	Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. <i>European Urology</i> , <b>2011</b> , 60, 920-30	10.2	60
119	Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. <i>European Urology</i> , <b>2011</b> , 60, 935-43	10.2	163
118	A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. <i>Prostate</i> , <b>2011</b> , 71, 1587-94	4.2	18
117	Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. <i>Cancer</i> , <b>2011</b> , 117, 3953-62	6.4	44
116	Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. <i>Cancer</i> , <b>2011</b> , 117, 5029-38	6.4	31
115	Penile Rehabilitation After Robotic Radical Prostatectomy: The Best Strategy <b>2011</b> , 361-370		
114	Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. <i>BJU International</i> , <b>2010</b> , 105, 1548-52	5.6	41
113	[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. <i>Journal of Urology</i> , <b>2010</b> , 184, 938-43	2.5	63
112	PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 1106-16	8.8	104
111	When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. <i>European Urology</i> , <b>2010</b> , 57, 551-8	10.2	112
110	Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. <i>European Urology</i> , <b>2010</b> , 58, 687-700	10.2	118
109	Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. <i>European</i>		
	<i>Urology</i> , <b>2010</b> , 58, 882-92	10.2	75
108	<i>Urology</i> , <b>2010</b> , 58, 882-92  Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 149-55	10.2	13
108	Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical		
	Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 149-55  Erectile function rehabilitation in the radical prostatectomy patient. <i>Journal of Sexual Medicine</i> ,	1.1	13
107	Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 149-55  Erectile function rehabilitation in the radical prostatectomy patient. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 1687-98  Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal	1.1	13 85
107	Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 149-55  Erectile function rehabilitation in the radical prostatectomy patient. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 1687-98  Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2521-31  Unilateral prostate cancer cannot be accurately predicted in low-risk patients. <i>International Journal</i>	1.1	13 85 85

102	Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 498-504	1.1	27
101	Unsuccessful investigation of preoperative sexual health issues in the prostate cancer "couple": results of a real-life psychometric survey at a major tertiary academic center. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 3347-55	1.1	6
100	Suspected clinical T3 prostate cancer is associated with a high rate of negative extended biopsies: clinical implications. <i>European Urology</i> , <b>2009</b> , 55, 253-4	10.2	1
99	Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. <i>European Urology</i> , <b>2009</b> , 55, 607	10.2	
98	Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node	10.2	213
97	dissection and adjuvant therapy. European Urology, 2009, 55, 261-70  Rebuttal from Author re: George N. Thalmann. Positive Lymph Nodes at Lymphadenectomy for Prostate Cancer: Where Do We Set the Tiller? Eur Urol 2009;55:271\(\textit{D}\). European Urology, 2009, 55, 273-2	27 <sup>10.2</sup>	
96	Open to debate. The motion: Nomograms should become a routine tool in determining prostate cancer prognosis. <i>European Urology</i> , <b>2009</b> , 55, 743-7	10.2	8
95	Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. <i>European Urology</i> , <b>2009</b> , 55, 1003-11	10.2	138
94	Pelvic lymph node dissection in prostate cancer. European Urology, 2009, 55, 1251-65	10.2	356
93	Editorial comment on: Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. <i>European Urology</i> , <b>2009</b> , 56, 667-8	10.2	1
92	Prediction of sexual function after radical prostatectomy. <i>Cancer</i> , <b>2009</b> , 115, 3150-9	6.4	31
91	The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. <i>International Journal of Urology</i> , <b>2009</b> , 16, 526-9	2.3	15
90	Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. <i>International Journal of Urology</i> , <b>2009</b> , 16, 676-81	2.3	8
89	Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. <i>Urology</i> , <b>2009</b> , 73, 850-5	1.6	15
88	Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. <i>Urology</i> , <b>2009</b> , 73, 1087-91	1.6	93
87	Prevention and Management of Postprostatectomy Erectile Dysfunction. <i>European Urology Supplements</i> , <b>2009</b> , 8, 80-87	0.9	3
86	The Triad of Endothelial Dysfunction, Cardiovascular Disease, and Erectile Dysfunction: Clinical Implications. <i>European Urology Supplements</i> , <b>2009</b> , 8, 58-66	0.9	14
85	Benign Prostatic Hyperplasia and Its Aetiologies. <i>European Urology Supplements</i> , <b>2009</b> , 8, 865-871	0.9	75

# (2008-2009)

84	Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. <i>Current Opinion in Urology</i> , <b>2009</b> , 19, 38-43	2.8	37
83	The Utility of PDE5 Inhibitors After Radical Prostatectomy <b>2009</b> , 177-196		
82	A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. <i>BJU International</i> , <b>2008</b> , 101, 556-60	5.6	21
81	Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. <i>BJU International</i> , <b>2008</b> , 101, 1513-8	5.6	122
80	Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement. <i>European Urology</i> , <b>2008</b> , 53, 1180-5	10.2	30
79	Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. <i>European Urology</i> , <b>2008</b> , 53, 564-70	10.2	70
78	Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial. <i>European Urology</i> , <b>2008</b> , 53, 967-73	10.2	43
77	Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level European Urology, <b>2008</b> , 53, 750-7	10.2	19
76	Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. <i>European Urology</i> , <b>2008</b> , 53, 794-802	10.2	124
75	Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. <i>European Urology</i> , <b>2008</b> , 54, 118-25	10.2	43
74	11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. <i>European Urology</i> , <b>2008</b> , 54, 392-401	10.2	202
73	Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. <i>European Urology</i> , <b>2008</b> , 54, 794-802	10.2	52
72	Remembered International Index of Erectile Function domain scores are not accurate in assessing preoperative potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 677-83	1.1	32
71	Intraoperative assessment of an implantable electrode array for cavernous nerve stimulation. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 1949-54	1.1	20
70	Should We Use Nomograms to Predict Outcome?. European Urology Supplements, 2008, 7, 396-399	0.9	6
69	The importance of the extent of pelvic-lymph-node dissection in the diagnosis of lymph-node metastases in prostate cancer. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 915-7; author reply 917-8	21.7	8
68	CURRENTLY USED CRITERIA FOR ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER. AN ANALYSIS OF PATHOLOGICAL FEATURES. <i>Journal of Urology</i> , <b>2008</b> , 179, 152-152	2.5	71
67	Re: Orgasm associated incontinence (climacturia) following radical pelvic surgery: rates of occurrence and predictors. J. M. Choi, C. J. Nelson, J. Stasi and J. P. Mulhall. J Urol 2007; 177: 2223-2226. <i>Journal of Urology</i> , <b>2008</b> , 180, 1187; author reply 1187-8	2.5	1

66	Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum. <i>Journal of Endourology</i> , <b>2008</b> , 22, 533-8	2.7	6
65	Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. <i>Cancer</i> , <b>2008</b> , 113, 2695-703	6.4	26
64	Development and external validation of an extended repeat biopsy nomogram. <i>Journal of Urology</i> , <b>2007</b> , 177, 510-5	2.5	72
63	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 791-5	7.5	42
62	A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. <i>BJU International</i> , <b>2007</b> , 99, 794-800	5.6	88
61	Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. <i>BJU International</i> , <b>2007</b> , 99, 1404-8	5.6	15
60	Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. <i>BJU International</i> , <b>2007</b> , 100, 528-32	5.6	32
59	Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. <i>BJU International</i> , <b>2007</b> , 100, 1249-53	5.6	13
58	A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. <i>European Urology</i> , <b>2007</b> , 51, 112-9; discussion 119-20	10.2	54
57	Initial biopsy outcome predictionhead-to-head comparison of a logistic regression-based nomogram versus artificial neural network. <i>European Urology</i> , <b>2007</b> , 51, 1236-40; discussion 1241-3	10.2	66
56	Development and external validation of an extended 10-core biopsy nomogram. <i>European Urology</i> , <b>2007</b> , 52, 436-44	10.2	91
55	Reply to Carsten Stephan et all Letter to the Editor re: Felix KH. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial Biopsy Outcome Prediction Head-to-Head Comparison of a Logistic Regression-Based	10.2	
54	Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. <i>European Urology</i> , <b>2007</b> , 52, 1374-80	10.2	16
53	Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. <i>European Urology</i> , <b>2007</b> , 52, 98-105	10.2	48
52	Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. <i>European Urology</i> , <b>2007</b> , 51, 1573-81	10.2	68
51	Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. <i>European Urology</i> , <b>2007</b> , 52, 733-43	10.2	29
50	Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. <i>European Urology</i> , <b>2007</b> , 52, 1067-	<del>1</del> 0.2	17
49	Preserved postoperative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy. <i>European Urology</i> , <b>2007</b> , 52, 702-7	10.2	56

# (2006-2007)

48	Management of erectile dysfunction after radical prostatectomy in 2007. <i>World Journal of Urology</i> , <b>2007</b> , 25, 143-8	4	29
47	Lower urinary tract symptoms and sexual dysfunction in women. <i>Current Sexual Health Reports</i> , <b>2007</b> , 4, 85-90	1.2	1
46	Multi-institutional validation of a new renal cancer-specific survival nomogram. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1316-22	2.2	387
45	Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. <i>Urology</i> , <b>2007</b> , 69, 147-51	1.6	131
44	The Evolution of Staging of Lymph Node Metastases in Clinically Localized Prostate Cancer. <i>EAU-EBU Update Series</i> , <b>2007</b> , 5, 153-162		4
43	Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 375-82	7.5	20
42	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 536-43	7.5	69
41	Prostate volume and adverse prostate cancer features: fact not artifact. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2669-77	7.5	66
40	Baseline potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. <i>European Urology</i> , <b>2006</b> , 50, 360-5	10.2	63
39	The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. <i>European Urology</i> , <b>2006</b> , 49, 273-8; discussion 278-9	10.2	41
38	Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?. European Urology, 2006, 49, 979-86	10.2	22
37	Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. <i>European Urology</i> , <b>2006</b> , 49, 1019-26; discussion 1026-7	10.2	180
36	High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. <i>European Urology</i> , <b>2006</b> , 50, 58-62; discussion 62-3	10.2	18
35	Women's sexual dysfunction: a review of the "surgical landscape". European Urology, <b>2006</b> , 50, 44-52	10.2	19
34	Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. <i>European Urology</i> , <b>2006</b> , 50, 563-8	10.2	264
33	Outcomes research: a methodologic review. <i>European Urology</i> , <b>2006</b> , 50, 218-24	10.2	14
32	Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. <i>European Urology</i> , <b>2006</b> , 50, 721-31	10.2	166
31	Prostate cancer nomograms: an update. <i>European Urology</i> , <b>2006</b> , 50, 914-26; discussion 926	10.2	65

30	Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. <i>European Urology</i> , <b>2006</b> , 50, 1006-13	10.2	266
29	Words of wisdom. Re: Detection of occult nodal metastases in locally advanced node-negative prostate cancer. <i>European Urology</i> , <b>2006</b> , 50, 1120-1	10.2	
28	Penile rehabilitation after radical prostatectomy. <i>Nature Reviews Urology</i> , <b>2006</b> , 3, 400-1		14
27	Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. <i>European Heart Journal</i> , <b>2006</b> , 27, 2632-9	9.5	297
26	A comparative review of apomorphine formulations for erectile dysfunction: recommendations for use in the elderly. <i>Drugs and Aging</i> , <b>2006</b> , 23, 309-19	4.7	3
25	Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. <i>Journal of Urology</i> , <b>2006</b> , 175, 1817-21	2.5	129
24	Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up?. <i>Urology</i> , <b>2006</b> , 67, 1193-8	1.6	59
23	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. <i>BJU International</i> , <b>2006</b> , 98, 329-34	5.6	110
22	Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. <i>BJU International</i> , <b>2006</b> , 98, 788-93	5.6	137
21	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. <i>BJU International</i> , <b>2006</b> , 98, 1204-9	5.6	56
20	Reliability of classification of erectile function domain of the international index of erectile function in patients affected by localized prostate cancer who are candidates for radical prostatectomy. <i>Urology</i> , <b>2005</b> , 66, 1140; author reply 1140-1	1.6	8
19	Safety and tolerability of oral erectile dysfunction treatments in the elderly. <i>Drugs and Aging</i> , <b>2005</b> , 22, 323-38	4.7	5
18	Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. <i>European Urology</i> , <b>2005</b> , 47, 612-21	10.2	31
17	Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy. <i>European Urology</i> , <b>2005</b> , 48, 938-45	10.2	118
16	The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 19M-23M	3	201
15	Association between erectile dysfunction and coronary artery disease: a case report study. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 575-82	1.1	24
14	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. <i>World Journal of Urology</i> , <b>2005</b> , 23, 374-84	4	25
13	Penile implants in the era of oral drug treatment for erectile dysfunction. <i>BJU International</i> , <b>2004</b> , 94, 745-51	5.6	25

#### LIST OF PUBLICATIONS

12	Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. <i>European Urology</i> , <b>2004</b> , 45, 123-33	10.2	104
11	Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. <i>European Urology</i> , <b>2004</b> , 45, 642-8; discussion 648	10.2	258
10	A Critical assessment of extracorporeal shock-wave therapy for Peyroniell disease. <i>Current Sexual Health Reports</i> , <b>2004</b> , 1, 19-23	1.2	
9	Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. <i>Journal of Urology</i> , <b>2004</b> , 172, 1926-9	2.5	239
8	Is There a Link between Erectile Dysfunction and Coronary Artery Disease?. <i>EAU Update Series</i> , <b>2004</b> , 2, 43-48		3
7	Common grounds for erectile dysfunction and coronary artery disease. <i>Current Opinion in Urology</i> , <b>2004</b> , 14, 361-5	2.8	81
6	The use of phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Current Opinion in Urology</i> , <b>2004</b> , 14, 357-9	2.8	11
5	The role of the urologist in the management of female sexual dysfunctions. <i>Current Opinion in Urology</i> , <b>2004</b> , 14, 389-93	2.8	14
4	Peyronie's disease: a review. Current Opinion in Urology, 2003, 13, 417-22	2.8	21
3	Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. <i>European Urology</i> , <b>2003</b> , 44, 360-4; discussion 364-5	10.2	401
2	The ageing male and erectile dysfunction. World Journal of Urology, 2002, 20, 28-35	4	8
1	Emerging treatment landscape of non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> ,1-18	5.4	О